pharmaphorum

OCTOBER 19, 2020

MCL is generally treated first with chemotherapy, and patients whose disease progresses despite that can then receive stem cell transplantation or BTK inhibitor drugs like Johnson & Johnson/AbbVie’s Imbruvica (ibrutinib) and AstraZeneca’s Calquence (acalabrutinib). billion acquisition of Kite in 2017.

Chemotherapy

pharmaphorum

JULY 2, 2021

The decision comes after FDA advisors voted six to two in April that Keytruda (pembrolizumab) should not stay on the market as a treatment option for patients with PD-L1-expressing gastric or gastroesophageal junction (GEJ) adenocarcinoma in patients who have received two or more earlier lines of therapy.

FDA

pharmaphorum

MARCH 2, 2021

Merck & Co has voluntarily withdrawn its Keytruda immunotherapy from a lung cancer niche in the US, amid a crackdown by the FDA on drugs approved without the required post-marketing data. Merck & Co said it had withdrawn the indication after consultation with the FDA and is working to complete the process over the coming weeks.

FDA

pharmaphorum

DECEMBER 21, 2020

California-based Gilead announced its strong intentions in oncology in 2017 with its $11.9 months in patients treated with chemotherapy. Sanofi’s acquisition builds on a partnership to develop central nervous system drugs that began in late 2017. billion (see below). months, compared with 6.7 Johnson and Johnson & Momenta.

Chemotherapy

pharmaphorum

MARCH 8, 2021

AZ is seeking to use Lynparza in patients who had also been previously treated with the chemotherapy drug docetaxel, but NICE has concluded that the application failed to provide evidence of the PARP inhibitor’s value compared to standard therapy.

Chemotherapy

European Pharmaceutical Review

OCTOBER 19, 2023

How do you perceive radiopharmaceuticals complementing existing cancer treatments, such as chemotherapy and immunotherapy? This has been demonstrated recently with PLUVICTO ® , which was the first US Food and Drug Administration (FDA)-approved targeted radioligand therapy for eligible patients with prostate cancer. cited 2023Oct].

Chemotherapy

Pharmaceutical Technology

MARCH 30, 2023

The PD-1 inhibitor received an accelerated approval for this indication back in May 2017. On March 27, MSD announced that the combined use of Keytruda with chemotherapy significantly improved progression-free survival versus the chemotherapy alone, as a first-line therapy for advanced or recurrent endometrial carcinoma.

Chemotherapy

European Pharmaceutical Review

MAY 4, 2023

Amivantamab was the first bispecific monoclonal antibody (BsMAb) approved in the EU to treat advanced NSCLC with EGFR exon 20 insertion mutations post chemotherapy. They are not US Food and Drug Administration (FDA)-approved for these patients due to the lack of benefit. 2017; 8(43): 75712–26. Personalized medicine at FDA.

Immunization

pharmaphorum

APRIL 30, 2021

The FDA’s Oncologic Drugs Advisory Committee (ODAC) has voted to strip Merck & Co’s Keytruda of its accelerated approval in gastric and gastroesophageal junction (GEJ) cancer, despite a lack of treatment options in these patients. .

Chemotherapy

pharmaphorum

FEBRUARY 2, 2021

Incyte has filed its PD-1 inhibitor retifanlimab with the FDA, seeking approval to treat a form of anal cancer associated with human papillomavirus (HPV) and HIV infections. It may get the nod before GlaxoSmithKline’s dostarlimab , also under review at the FDA for endometrial cancer.

Chemotherapy

European Pharmaceutical Review

JANUARY 3, 2023

Arm A participants will be treated with Cisplatin-based chemotherapy without receiving SENS-401. Arm B participants will receive 43.5mg of oral SENS-401 one week prior to getting cisplatin treatment, during the whole duration of the chemotherapy treatment and four weeks after receiving the last cycle of cisplatin.

Chemotherapy

pharmaphorum

OCTOBER 11, 2020

The phase 3 PENELOPE-B trial was testing the CDK4/6 inhibitor as a potential treatment for early breast cancer patients who have residual invasive disease following neoadjuvant (pre-surgery) chemotherapy, but failed to show an improvement on the main measure of improved disease-free survival (iDFS).

Chemotherapy

Roots Analysis

OCTOBER 4, 2023

During the research, I noticed a significant increase in the number of FDA approvals for bispecific antibodies in recent years. One area of interest is in oncology , where bispecific antibodies can be used to target two different antigens at the same time, leading to improved efficacy and reduced toxicity compared to traditional chemotherapy.

Chemotherapy

ISPE

MAY 10, 2023

Mexican Governor: Cancer Children Given Water Instead of Chemotherapy.” Published 19 January 2017. Presented at the 2017 IFIP/IEEE Symposium on Integrated Network and Service Management (IM), Lisbon, Portugal, 8–12 May 2017: 772–77. 30 June 2016. link] 6 BBC News. link] 7 He, J., Cai, and X. doi: 10.1109/TSP.2020.3006760

Chemotherapy

The Checkup by Singlecare

DECEMBER 6, 2023

Furosemide, also known by its brand name Lasix, is approved by the United States Food and Drug Administration (FDA) and is available in several forms, including oral tablet, oral solution, and injection. Cisplatin Cisplatin is a chemotherapy drug used to treat certain types of cancers.

Chemotherapy

The Thyroid Pharmacist

SEPTEMBER 20, 2024

Plecanatide : This is one of the newest medications for IBS-C that has been approved by the FDA. Tenapanor : Tenapanor was approved by the FDA in September of 2019 for IBS-C. [45] As the intestines are made of smooth muscles, a reduction in the action of these muscles can slow down digestion and cause constipation. April 4, 2017.

Health and Personal Care Stores

European Pharmaceutical Review

MAY 23, 2024

Last month, CARVYKTI ® (ciltacabtagene autoleucel; cilta-cel) was the first BCMA-targeted CAR-T cell therapy to be approved for second-line treatment of multiple myeloma by the US Food and Drug Administration (FDA). How has the autologous T-cell immunotherapy field progressed in recent years?

Medical Schools

pharmaphorum

SEPTEMBER 25, 2020

Furthermore, the duration of response with the PD-1 checkpoint inhibitor was nearly five times longer at 29 months versus just over six months with frontline chemotherapy. The drug is approved both as a monotherapy in first-line NSCLC and also got the green light for use in combination with chemo in 2017. of the chemo group.

Chemotherapy

European Pharmaceutical Review

DECEMBER 21, 2023

The UK’s National Institute for Health and Care Excellence (NICE) has issued Final Draft Guidance recommending Lynparza (olaparib) for use as combination therapy with abiraterone and prednisone or prednisolone, for untreated hormone-relapsed metastatic prostate cancer in adults who cannot have or do not want chemotherapy.

Chemotherapy

pharmaphorum

JULY 1, 2025

billion, Amgen has promising phase 3 results with a drug for gastric cancer that was the focal point for the deal. billion, Amgen has promising phase 3 results with a drug for gastric cancer that was the focal point for the deal. billion, Amgen has promising phase 3 results with a drug for gastric cancer that was the focal point for the deal.

Pharmaceutical Companies

pharmaphorum

SEPTEMBER 8, 2020

In England for instance, the introduction of a biosimilar to prevent neutropenia in patients undergoing chemotherapy, resulted in a number of Strategic Health Authorities reassessing their guidance relating to this medicine. 2017;(13):47-64. Unpleasant truth: let’s embrace it and take action. 10 Wait S, Han D, Muthu V, et al.

Chemotherapy

pharmaphorum

MARCH 18, 2021

AstraZeneca’s BTK inhibitor Calquence has become the first targeted oral therapy to be backed by NICE for NHS England patients with chronic lymphocytic leukaemia (CLL) who can’t be treated with first-line chemotherapy. Daiichi Sankyo gets okay for cholesterol drugs.

Hospitals

pharmaphorum

OCTOBER 27, 2022

HRD is now used as a biomarker for administering PARP inhibitors or platinum-based chemotherapy (such as cisplatin or carboplatin) to ovarian cancer patients. PARP inhibitors, which are now used as a first-line management in newly diagnosed individuals, include the FDA-approved olaparib, as well as rucaparib and niraparib.

Chemotherapy

pharmaphorum

JUNE 13, 2022

Three years after Daiichi Sankyo’s FLR3 inhibitor quizartinib was rejected by the FDA, the drugmaker has reported the results of a new phase 3 trial that is key to getting the drug to the US market and chasing down rival drugs from Astellas and Novartis. Quizartinib plus standard chemotherapy reduced the risk of death by 22.4%

Chemotherapy

Hospital Pharmacy Europe

FEBRUARY 15, 2024

Bespoke, personalised blood cancer treatment was revolutionised by the approval of the first chimeric antigen receptor (CAR) T-cell therapy in 2017, and they continue to offer an improved quality of life for many patients. They are] administered by the same nurses who would normally give chemotherapy’, Dr Tucker says.

Chemotherapy

pharmaphorum

NOVEMBER 14, 2022

GSK has had another setback in its oncology business, after the FDA asked it to restrict use of its PARP inhibitor Zejula in ovarian, fallopian tube, or primary peritoneal cancer to patients with a specific mutation. That was due last Friday, but cancelled when GSK opted to withdraw the approval.

Labelling

The Checkup by Singlecare

NOVEMBER 13, 2023

According to the CDC , treatment includes surgery, chemotherapy, radiation therapy, targeted therapy, or a combination of these treatments. To help decrease the risk of shingles, Shingrix vaccine is FDA-approved for adults 50 and older. Antiviral medications such as Acyclovir ( zovirax ) and famciclovir are often prescribed.

Mayo Clinic

STAT

MARCH 6, 2023

Still, when doctors told her last year that the cancer was growing despite two operations, radiation therapy, and a fifth regimen of chemotherapy, the retired business-meeting facilitator decided to do something unorthodox: spend $83,000 out of pocket on an unproven experimental cancer vaccine.

Vaccines